{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:35:21Z","timestamp":1793907321042,"version":"4.8.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Opportunistic infections (OIs), such as Pneumocystis jirovecii pneumonia (PJP), have been reported in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, and are an important cause of morbidity and mortality. Currently, there are no international consensus guidelines regarding the use of antimicrobial prophylaxis for OIs, and in particular PJP, in CLL patients treated with Bruton tyrosine kinase inhibitors (BTKi\u2019s). We evaluated the frequency of PJP in CLL patients at our institution who were treated with BTKi\u2019s, and assessed the impact of prophylaxis on reducing the risk of PJP. We identified 217 patients treated with BTKi\u2019s, consisting of 3 cohorts: 143 patients on either BTKi monotherapy with ibrutinib or acalabrutinib, 17 patients receiving ibrutinib combination therapy with umbralisib as part of a clinical trial, and 57 patients receiving ibrutinib in combination with standard chemotherapy, also as part of a clinical trial. Forty-one percent of patients on BTKi monotherapy received prophylaxis, which was given at the discretion of the treating physician. The prevalence of PJP in all patients not on prophylaxis was 3.4% (3 of 87), and, specifically in BTKi-monotherapy patients not on prophylaxis, the PJP prevalence was 2.4% (2 of 85). PJP prophylaxis was effective, as there were no cases of PJP in patients on prophylaxis (0 of 130). The relatively low prevalence of PJP in our study population suggests that routine prophylaxis may not be indicated in CLL patients on BTKi therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001678","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T15:47:38Z","timestamp":1586792858000},"page":"1458-1463","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors"],"prefix":"10.1182","volume":"4","author":[{"given":"Christine E.","family":"Ryan","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-2063","authenticated-orcid":false,"given":"Matthew P.","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"},{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas C.","family":"Issa","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"},{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA;"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"issue":"1","key":"2020041408480888300_B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2020041408480888300_B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2020041408480888300_B3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2020041408480888300_B4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2019;20(1):e10]","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020041408480888300_B5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"30","key":"2020041408480888300_B6","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"2020041408480888300_B7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2020041408480888300_B8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2020041408480888300_B9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"issue":"3","key":"2020041408480888300_B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020041408480888300_B11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2020041408480888300_B12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2020041408480888300_B13","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.1002\/ajh.24890","article-title":"Ibrutinib-associated Pneumocystis jirovecii pneumonia","volume":"92","author":"Lee","year":"2017","journal-title":"Am J Hematol"},{"issue":"15","key":"2020041408480888300_B14","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2020041408480888300_B15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2020041408480888300_B16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2020041408480888300_B17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"issue":"25","key":"2020041408480888300_B18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020041408480888300_B19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.15460","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia: a British Society for Haematology guideline","volume":"182","author":"Schuh","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2020041408480888300_B20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1378\/chest.07-0223","article-title":"Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients","volume":"132","author":"Boll\u00e9e","year":"2007","journal-title":"Chest"},{"issue":"8","key":"2020041408480888300_B21","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","article-title":"Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020041408480888300_B22","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2020041408480888300_B23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"16","key":"2020041408480888300_B24","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2020041408480888300_B25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1458\/1724382\/advancesadv2020001678.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1458\/1724382\/advancesadv2020001678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T12:48:26Z","timestamp":1586868506000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1458\/454336\/Pneumocystis-jirovecii-pneumonia-and-institutional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001678","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]}}}